UnknownPhase 3

Topical 0.5% Ivermectin Cream for Treatment of Demodicidosis

Israel50 participantsStarted 2014-02

Plain-language summary

The purpose of this study is to determine whether 0.5% ivermectin cream is effective in the treatment of demodicidosis (including papulopustular rosacea)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * subjects with clinical and laboratory diagnosis of demodicidosis with symmetrical facial eruption who are willing to comply with study requirements Exclusion Criteria: * known hypersensitivity to ivermectin. * pregnancy * immunodeficiency such as HIV or immunosuppressive therapy * concomitant use of systemic antibiotics or steroids

What they're measuring

A decrease in mite density in skin surface biopsy after treatment with topical ivermectin (≤5 mites/cm2 for skin lesions).

Timeframe: 5 months

Trial details

NCT IDNCT02036229

SponsorRabin Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-12

Contact for this trial

Rina Segal, MD

972505206134 rinas3@clalit.org.il

View on ClinicalTrials.gov More Demodicidosis trials